Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates

Nancy J. Sullivan, Thomas Geisbert, Joan B. Gelsbert, Ling Xu, Zhi Yong Yang, Mario Roederer, Richard A. Koup, Peter B. Jahrling, Gary J. Nabel

Research output: Contribution to journalArticle

377 Citations (Scopus)

Abstract

Containment of highly lethal Ebola virus outbreaks poses a serious public health challenge. Although an experimental vaccine has successfully protected non-human primates against disease, more than six months was required to complete the immunizations, making it impractical to limit an acute epidemic. Here, we report the development of accelerated vaccination against Ebola virus in non-human primates. The antibody response to immunization with an adenoviral (ADV) vector encoding the Ebola glycoprotein (GP) was induced more rapidly than with DNA priming and ADV boosting, but it was of lower magnitude. To determine whether this earlier immune response could nonetheless protect against disease, cynomolgus macaques were challenged with Ebola virus after vaccination with ADV-GP and nucleoprotein (NP) vectors. Protection was highly effective and correlated with the generation of Ebola-specific CD8+ T-cell and antibody responses. Even when animals were immunized once with ADV-GP/NP and challenged 28 days later, they remained resistant to challenge with either low or high doses of virus. This accelerated vaccine provides an intervention that may help to limit the epidemic spread of Ebola, and is applicable to other viruses.

Original languageEnglish (US)
Pages (from-to)681-684
Number of pages4
JournalNature
Volume424
Issue number6949
DOIs
StatePublished - Aug 7 2003
Externally publishedYes

Fingerprint

Ebola Hemorrhagic Fever
Ebolavirus
Primates
Glycoproteins
Vaccination
Nucleoproteins
Antibody Formation
Primate Diseases
Immunization
Vaccines
Viruses
Macaca
Disease Outbreaks
Public Health
T-Lymphocytes
DNA

ASJC Scopus subject areas

  • General

Cite this

Sullivan, N. J., Geisbert, T., Gelsbert, J. B., Xu, L., Yang, Z. Y., Roederer, M., ... Nabel, G. J. (2003). Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature, 424(6949), 681-684. https://doi.org/10.1038/nature01876

Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. / Sullivan, Nancy J.; Geisbert, Thomas; Gelsbert, Joan B.; Xu, Ling; Yang, Zhi Yong; Roederer, Mario; Koup, Richard A.; Jahrling, Peter B.; Nabel, Gary J.

In: Nature, Vol. 424, No. 6949, 07.08.2003, p. 681-684.

Research output: Contribution to journalArticle

Sullivan, NJ, Geisbert, T, Gelsbert, JB, Xu, L, Yang, ZY, Roederer, M, Koup, RA, Jahrling, PB & Nabel, GJ 2003, 'Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates', Nature, vol. 424, no. 6949, pp. 681-684. https://doi.org/10.1038/nature01876
Sullivan NJ, Geisbert T, Gelsbert JB, Xu L, Yang ZY, Roederer M et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature. 2003 Aug 7;424(6949):681-684. https://doi.org/10.1038/nature01876
Sullivan, Nancy J. ; Geisbert, Thomas ; Gelsbert, Joan B. ; Xu, Ling ; Yang, Zhi Yong ; Roederer, Mario ; Koup, Richard A. ; Jahrling, Peter B. ; Nabel, Gary J. / Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. In: Nature. 2003 ; Vol. 424, No. 6949. pp. 681-684.
@article{3ac7c7789bb24b21b821b8ea375dde65,
title = "Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates",
abstract = "Containment of highly lethal Ebola virus outbreaks poses a serious public health challenge. Although an experimental vaccine has successfully protected non-human primates against disease, more than six months was required to complete the immunizations, making it impractical to limit an acute epidemic. Here, we report the development of accelerated vaccination against Ebola virus in non-human primates. The antibody response to immunization with an adenoviral (ADV) vector encoding the Ebola glycoprotein (GP) was induced more rapidly than with DNA priming and ADV boosting, but it was of lower magnitude. To determine whether this earlier immune response could nonetheless protect against disease, cynomolgus macaques were challenged with Ebola virus after vaccination with ADV-GP and nucleoprotein (NP) vectors. Protection was highly effective and correlated with the generation of Ebola-specific CD8+ T-cell and antibody responses. Even when animals were immunized once with ADV-GP/NP and challenged 28 days later, they remained resistant to challenge with either low or high doses of virus. This accelerated vaccine provides an intervention that may help to limit the epidemic spread of Ebola, and is applicable to other viruses.",
author = "Sullivan, {Nancy J.} and Thomas Geisbert and Gelsbert, {Joan B.} and Ling Xu and Yang, {Zhi Yong} and Mario Roederer and Koup, {Richard A.} and Jahrling, {Peter B.} and Nabel, {Gary J.}",
year = "2003",
month = "8",
day = "7",
doi = "10.1038/nature01876",
language = "English (US)",
volume = "424",
pages = "681--684",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "6949",

}

TY - JOUR

T1 - Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates

AU - Sullivan, Nancy J.

AU - Geisbert, Thomas

AU - Gelsbert, Joan B.

AU - Xu, Ling

AU - Yang, Zhi Yong

AU - Roederer, Mario

AU - Koup, Richard A.

AU - Jahrling, Peter B.

AU - Nabel, Gary J.

PY - 2003/8/7

Y1 - 2003/8/7

N2 - Containment of highly lethal Ebola virus outbreaks poses a serious public health challenge. Although an experimental vaccine has successfully protected non-human primates against disease, more than six months was required to complete the immunizations, making it impractical to limit an acute epidemic. Here, we report the development of accelerated vaccination against Ebola virus in non-human primates. The antibody response to immunization with an adenoviral (ADV) vector encoding the Ebola glycoprotein (GP) was induced more rapidly than with DNA priming and ADV boosting, but it was of lower magnitude. To determine whether this earlier immune response could nonetheless protect against disease, cynomolgus macaques were challenged with Ebola virus after vaccination with ADV-GP and nucleoprotein (NP) vectors. Protection was highly effective and correlated with the generation of Ebola-specific CD8+ T-cell and antibody responses. Even when animals were immunized once with ADV-GP/NP and challenged 28 days later, they remained resistant to challenge with either low or high doses of virus. This accelerated vaccine provides an intervention that may help to limit the epidemic spread of Ebola, and is applicable to other viruses.

AB - Containment of highly lethal Ebola virus outbreaks poses a serious public health challenge. Although an experimental vaccine has successfully protected non-human primates against disease, more than six months was required to complete the immunizations, making it impractical to limit an acute epidemic. Here, we report the development of accelerated vaccination against Ebola virus in non-human primates. The antibody response to immunization with an adenoviral (ADV) vector encoding the Ebola glycoprotein (GP) was induced more rapidly than with DNA priming and ADV boosting, but it was of lower magnitude. To determine whether this earlier immune response could nonetheless protect against disease, cynomolgus macaques were challenged with Ebola virus after vaccination with ADV-GP and nucleoprotein (NP) vectors. Protection was highly effective and correlated with the generation of Ebola-specific CD8+ T-cell and antibody responses. Even when animals were immunized once with ADV-GP/NP and challenged 28 days later, they remained resistant to challenge with either low or high doses of virus. This accelerated vaccine provides an intervention that may help to limit the epidemic spread of Ebola, and is applicable to other viruses.

UR - http://www.scopus.com/inward/record.url?scp=0042739176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042739176&partnerID=8YFLogxK

U2 - 10.1038/nature01876

DO - 10.1038/nature01876

M3 - Article

VL - 424

SP - 681

EP - 684

JO - Nature

JF - Nature

SN - 0028-0836

IS - 6949

ER -